Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.

Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JM, Artis E, Purkayastha D, Thomas JD, Solomon SD; VALIDD Investigators.

Am Heart J. 2006 Aug;152(2):246-52.

PMID:
16875904
3.

Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.

Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM; Valsartan in Renal Transplantation Group.

Transplant Proc. 2006 Oct;38(8):2419-23.

PMID:
17097955
4.

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.

Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; Valsartan In Diastolic Dysfunction (VALIDD) Investigators.

Lancet. 2007 Jun 23;369(9579):2079-87.

PMID:
17586303
6.

Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.

Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P.

J Clin Pharmacol. 2007 Mar;47(3):397-403.

PMID:
17322151
7.

Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.

Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators.

J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38.

PMID:
16645357
8.

EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics.

Hassanein A, Desai A, Verma A, Oparil S, Izzo J, Rocha R, Hilkert R, Seifu Y, Pitt B, Solomon S.

Ther Adv Cardiovasc Dis. 2009 Dec;3(6):429-39. doi: 10.1177/1753944709341301. Epub 2009 Jul 28.

PMID:
19638366
9.

Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.

Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.

Hypertens Res. 2007 Apr;30(4):307-13.

PMID:
17541209
10.

[Valsartan improves symptoms and quality of life in patients with chronic heart failure].

Baumhäkel M, Müller U, Böhm M.

MMW Fortschr Med. 2008 Apr 10;150 Suppl 1:48-53. German.

PMID:
18540333
11.

Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.

van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJ.

Circulation. 2013 Jan 22;127(3):322-30. doi: 10.1161/CIRCULATIONAHA.112.135392. Epub 2012 Dec 17.

12.

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.

Mistry NB, Westheim AS, Kjeldsen SE.

Expert Opin Pharmacother. 2006 Apr;7(5):575-81. Review.

PMID:
16553573
13.
14.

Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.

Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A.

Curr Med Res Opin. 2008 Aug;24(8):2303-11. doi: 10.1185/03007990802271946. Epub 2008 Jun 28.

PMID:
18593517
15.
16.

Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker.

Kamezaki F, Tasaki H, Yamashita K, Shibata K, Hirakawa N, Tsutsui M, Kouzuma R, Nagatomo T, Adachi T, Otsuji Y.

Hypertens Res. 2007 Aug;30(8):699-706.

PMID:
17917317
17.

Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.

Zhu S, Liu Y, Wang L, Meng QH.

Nephrol Dial Transplant. 2008 Sep;23(9):2841-6. doi: 10.1093/ndt/gfn159. Epub 2008 Apr 5.

PMID:
18390891
18.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
19.

Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.

Nash DT, Crikelair N, Zappe D.

Curr Med Res Opin. 2008 Sep;24(9):2617-26. doi: 10.1185/03007990802333282 . Epub 2008 Aug 6.

PMID:
18687165
20.

Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension.

Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J.

J Cardiovasc Pharmacol. 2005 Dec;46(6):735-9.

PMID:
16306795

Supplemental Content

Support Center